GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

BridgeBio Oncology Therapeutics BBOT · USD

N/A · US listing · 🇺🇸 United States

Compare

2.30

+12.75%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About BridgeBio Oncology Therapeutics

Its shares trade under the ticker BBOT. It has been listed since 9 February 2024.

Helix Acquisition Corp II is a US-based company operating in industry. The company is headquartered in Boston, Massachusetts. The company went IPO on 2024-02-09. Helix Acquisition Corp. II is a blank check company. The firm is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which it refers to as its initial business combination. The firm has not selected any specific business combination target and it has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination. While it may pursue a business combination target in any business or industry, it intends to focus on healthcare or healthcare related industries. The firm has not generated any revenue.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
9 Feb 2024
Employees
92
Head office
256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO, CA, 94080
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Ms. Bihua ChenChairman of the Board, Chief Executive Officer
  • Mr. Caleb TrippChief Financial Officer
  • Mr. Nebojsa ObradovicChief Legal Officer
  • Mr. Mark MckennaIndependent Director
  • Mr. John SchmidIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Helix Acquisition Corp II has a strong focus on healthcare industry for its initial business combination.
  • The company is listed on 9 February 2024 with 92 employees in Boston.
  • It targets healthcare-related industries for potential business combinations.

Weaknesses

  • Helix Acquisition Corp II has not selected any specific business combination target yet.
  • The firm has not generated any revenue since its formation.
  • No substantive discussions have been held with any business combination target.

Opportunities

  • The healthcare industry offers significant growth opportunities for Helix Acquisition Corp II.
  • The company can leverage its focus on healthcare to find suitable business combinations.
  • Boston's healthcare ecosystem provides a strategic location for potential partnerships.

Threats

  • The lack of a selected business combination target poses a risk to Helix Acquisition Corp II.
  • No revenue generation since formation may deter potential investors.
  • Blank check companies face regulatory scrutiny in the healthcare sector.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.